Consider shorting quantum computing stocks QUBT and IONQ, which are viewed as fundamentally weak due to massive shareholder dilution. The price target for QUBT is a return to "$1.00", reflecting an extremely bearish outlook. A strong sell recommendation also exists for Rigetti Computing (RGTI), with a belief that its fair value is "$1.00 or less". A short position on Praxis Precision Medicines (PRAX) is favored due to its planned public offering, which could pressure the stock price. In contrast to these bearish calls, Spruce (SPRU) is presented as a direct buy recommendation.

Quantum Computing (QUBT & IONQ)

The host expressed an extremely bearish (negative) view on quantum computing stocks, specifically mentioning QUBT and IonQ.

• He stated he has a short position on "Quantum" and has "shorted more." • He referred to QUBT as a "fake ass company" and "dog crap company," believing its stock price should be significantly lower. - He noted that the number of outstanding shares for QUBT increased dramatically from 99 million to 159 million, indicating significant shareholder dilution. - He pointed out that the company had only $3 million in cash at one point, highlighting a weak financial position before it raised more money. - Price Target: The host believes the stock should go "back to a dollar" and become a "penny stock." • Regarding IonQ (IONQ), he mentioned adding to his short position and joked that for him to make money, the stock "might have to go negative."

Takeaways

• The host's sentiment is overwhelmingly bearish on these quantum computing stocks due to what he perceives as poor fundamentals and excessive share dilution. • A short position is a high-risk strategy where an investor profits if a stock's price goes down. The host's commentary suggests he believes there is a high probability of this happening for QUBT and IONQ. • The mention of massive increases in shares outstanding is a significant red flag for investors, as it dilutes the ownership stake of existing shareholders and can put downward pressure on the stock price.

Rigetti Computing (RGTI)

The host is extremely bearish on Rigetti Computing.

• He stated, "Rigetti's worth a dollar, if that. It's not worth a dollar." • He expressed disbelief at its current trading price (mentioned as "$47" in the transcript) and urged listeners to "Sell this shit."

Takeaways

• This is a strong, direct sell recommendation from the host. • The sentiment is that the company is fundamentally overvalued and its stock price is destined to fall significantly. • The host's price target is $1.00 or less, representing a massive potential downside from the price mentioned in the discussion.

Praxis Precision Medicines (PRAX)

The host's sentiment towards Praxis appears to be bearish.

• When a listener suggested an "ultra short for prax," the host responded enthusiastically: "Ooh, I like that. When you say ultra, I get excited." • A news headline mentioned later in the transcript states, "Praxis Precision Medicine's plans public offering."

Takeaways

• The host's comments suggest he is considering or supports a short position on PRAX. • The planned public offering is a key piece of information. Companies issue new shares to raise capital, but this action often dilutes existing shareholders and can cause the stock price to decrease in the short term. This news could be the catalyst for the host's bearish view.

Spruce (SPRU)

The host expressed a clear and direct bullish (positive) view on Spruce.

• He stated simply, "I think it's still a buy. Spruce is still a buy. Spruce Moose."

Takeaways

• This is a direct buy recommendation from the host. • No specific reasons, price targets, or timelines were provided in the transcript to support this bullish stance.

Investment Theme: Pharmaceutical Drug Pricing

A significant portion of the transcript involved a speech (impersonating Donald Trump) outlining a plan to dramatically lower drug prices in the U.S., particularly for fertility treatments and weight loss drugs.

• The core of the plan is to enforce "most favored nation" pricing, meaning drug companies would be forced to sell their drugs in the U.S. at the lowest price they offer anywhere in the world. • EMD Serono (a subsidiary of Merck KGaA, MKKGY), the world's largest fertility drug manufacturer, was said to have agreed to provide "massive discounts" on drugs like Gonal-F. • The plan would also expedite the approval of competing drugs, such as Pergoveris, to break up monopolies and drive down prices. • Pfizer (PFE) and AstraZeneca (AZN) were mentioned as other companies that have made similar pricing deals. • The popular weight-loss drug Ozempic (made by Novo Nordisk, NVO) was used as an example of a drug that could see its price fall from $1,300 to around $150.

Takeaways

• This theme represents a significant potential risk factor for the entire pharmaceutical and biotech industry, especially companies with high U.S. sales. • If such policies were implemented, companies like Novo Nordisk (NVO), Eli Lilly (LLY) (maker of similar weight-loss drugs), and fertility drug manufacturers could see a dramatic reduction in revenue and profit margins. • Conversely, the plan also mentioned creating new "fertility insurance" plans, which could increase the volume of patients seeking treatment, potentially offsetting some of the revenue loss from lower prices.

Bitcoin (BTC)

Bitcoin was mentioned once in a news headline segment.

• The headline stated: "Top cryptocurrencies fall, Bitcoin heathers above $108,000."

Takeaways

• This was presented as a market data point from a future date (October 2025). It is not an analysis or recommendation from the host. • The price of $108,000 is a significant data point within the context of the podcast's fictional timeline.

Market News & Headlines

The following is a summary of corporate news items read during the podcast. These are factual announcements and not direct opinions from the host.

• ATI Life Sciences (ATIP): Announced a proposed public offering of common shares.
• CSX Corporation (CSX): Q3 revenue and earnings beat analyst estimates.
• Community West Bank (CWBC): Q3 net income tripled due to loan growth.
• Doc Go (DCGO): Signed a deal to launch a Care Gap Closure Program in New Mexico.
• EQT Corporation (EQT): Increased its base dividend by 5%.
• FNB Corporation (FNB): Q3 adjusted EPS and revenue beat analyst estimates.
• Independent Bank Corp (INDB): Q3 adjusted EPS and revenue increased, beating estimates.
• Interactive Brokers (IBKR): Q3 profit, adjusted earnings, and revenue beat expectations; quarterly dividend was maintained.
• M&T Bank Corporation (MTB): Received a ratings downgrade to "Buy" from "Strong Buy" from an analyst.
• OZK Bank (OZK): Q3 EPS missed estimates, while revenue slightly beat estimates.
• Standard Lithium (SLI): Announced a proposed public offering of common shares.
• TeraWulf (WULF): Priced a $3.20 billion private offering of notes.
• Trimble (TRMB): An insider sold shares worth $567,375.
• Satellogic (SATL): An insider sold shares worth $1,197,997.
• Emergent BioSolutions (EBS): An insider sold shares worth $306,080.